AR056575A1 - Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararlo - Google Patents
Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararloInfo
- Publication number
- AR056575A1 AR056575A1 ARP060104441A ARP060104441A AR056575A1 AR 056575 A1 AR056575 A1 AR 056575A1 AR P060104441 A ARP060104441 A AR P060104441A AR P060104441 A ARP060104441 A AR P060104441A AR 056575 A1 AR056575 A1 AR 056575A1
- Authority
- AR
- Argentina
- Prior art keywords
- prolinamide
- fluorophenyl
- alpha
- phenyl
- prepare
- Prior art date
Links
- -1 2-FLUOROPHENYL Chemical class 0.000 title abstract 2
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002996 emotional effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0520581A GB0520581D0 (en) | 2005-10-10 | 2005-10-10 | Novel compounds |
| GB0523045A GB0523045D0 (en) | 2005-11-11 | 2005-11-11 | Novel compounds |
| GB0603900A GB0603900D0 (en) | 2006-02-27 | 2006-02-27 | Novel compounds |
| GB0618336A GB0618336D0 (en) | 2006-09-18 | 2006-09-18 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056575A1 true AR056575A1 (es) | 2007-10-10 |
Family
ID=37546777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104441A AR056575A1 (es) | 2005-10-10 | 2006-10-09 | Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararlo |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7655693B2 (enExample) |
| EP (1) | EP1934177B8 (enExample) |
| JP (1) | JP5139305B2 (enExample) |
| KR (1) | KR101282464B1 (enExample) |
| AR (1) | AR056575A1 (enExample) |
| AT (1) | ATE556049T1 (enExample) |
| AU (1) | AU2006301470B2 (enExample) |
| BR (1) | BRPI0616944B8 (enExample) |
| CA (1) | CA2625642C (enExample) |
| CR (1) | CR9898A (enExample) |
| EA (1) | EA015736B1 (enExample) |
| ES (1) | ES2387405T3 (enExample) |
| IL (1) | IL192627A0 (enExample) |
| MA (1) | MA29817B1 (enExample) |
| NO (1) | NO20082145L (enExample) |
| NZ (1) | NZ567051A (enExample) |
| PE (1) | PE20070592A1 (enExample) |
| PL (1) | PL1934177T3 (enExample) |
| TW (1) | TW200730494A (enExample) |
| WO (1) | WO2007042239A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8143306B2 (en) * | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
| US7855218B2 (en) * | 2005-10-10 | 2010-12-21 | Convergence Pharmaceuticals Limited | Compounds |
| GB0701365D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) * | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| WO2011015537A1 (en) | 2009-08-05 | 2011-02-10 | Glaxo Group Limited | Co-therapy for the treatment of epilepsy and related disorders |
| HRP20150491T1 (hr) | 2009-09-14 | 2015-08-14 | Convergence Pharmaceuticals Limited | PROCES PRIPREME DERIVATA α-KARBOKSAMIDA |
| ES2786298T3 (es) | 2011-03-03 | 2020-10-09 | Zalicus Pharmaceuticals Ltd | Inhibidores de benzimidazol del canal de sodio |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| CN106255679B (zh) | 2014-02-27 | 2019-09-06 | 默克专利有限公司 | 用作nav通道抑制剂的杂环化合物及其用途 |
| GB201417499D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| GB201417500D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| GB201417497D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| ES2912881T3 (es) | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
| CA3042384A1 (en) * | 2016-11-02 | 2018-05-11 | Biogen Ma Inc. | Novel dosage regimen |
| CA3062884A1 (en) * | 2017-05-19 | 2018-11-22 | Biogen Ma Inc. | Novel crystalline forms |
| EP3691634A4 (en) * | 2017-10-05 | 2021-03-31 | Biogen Inc. | PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES |
| CA3077088A1 (en) | 2017-10-10 | 2019-04-18 | Biogen Inc. | Process for preparing spiro derivatives |
| AU2019255519A1 (en) * | 2018-04-16 | 2020-10-01 | Biogen Ma Inc. | Methods of treating neuropathic pain |
| MX2021012421A (es) * | 2019-04-10 | 2022-02-10 | Biogen Inc | Procesos para preparar derivados de pirrolidina alfa-carboxamida. |
| EA202192762A1 (ru) * | 2019-04-10 | 2022-03-21 | Байоджен Ма Инк. | Способ получения производных альфа-карбоксамид пирролидина |
| EP4096508A4 (en) | 2020-01-30 | 2024-03-27 | Javed, Mohammad | COMBINATION MEDICINAL THERAPIES FOR CNS DISEASES |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US6201016B1 (en) | 1994-06-27 | 2001-03-13 | Cytomed Incorporated | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| US6136131A (en) * | 1998-06-02 | 2000-10-24 | Instrument Specialties Company, Inc. | Method of shielding and obtaining access to a component on a printed circuit board |
| RU2001129155A (ru) | 1999-03-26 | 2003-08-10 | Еро-Сельтик С.А. (Lu) | Соединения с арильными заместителями (варианты), фармацевтическая композиция и способ лечения расстройства, чувствительного к блокаде натриевых каналов у млекопитающего, способ лечения, профилактики различных заболеваний или уменьшения интенсивности гибели или потери нейронов (варианты), способ облегчения или предупреждения эпилептических припадков у животного (варианты), соединение - радиоактивный лиганд для участка связывания в натриевом канале |
| GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
| GB0115517D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| TW200404796A (en) * | 2002-08-19 | 2004-04-01 | Ono Pharmaceutical Co | Nitrogen-containing compound |
| MY134480A (en) * | 2002-09-20 | 2007-12-31 | Hoffmann La Roche | 4-pyrrolidino-phenyl-benzyl ether derivatives |
| AR044503A1 (es) | 2003-03-18 | 2005-09-14 | Merck & Co Inc | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
| CN101333192A (zh) | 2003-04-03 | 2008-12-31 | 默克公司 | 作为钠通道阻滞剂的联芳基取代吡唑 |
| JP2006523701A (ja) | 2003-04-18 | 2006-10-19 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャネルブロッカーとしてのビアリール置換チアゾール、オキサゾール、およびイミダゾール |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| EP1524265A1 (en) * | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
| WO2005100334A1 (en) * | 2004-04-14 | 2005-10-27 | Pfizer Products Inc. | Dipeptidyl peptidase-iv inhibitors |
| WO2006119451A1 (en) | 2005-05-04 | 2006-11-09 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyrazines useful as modulators of ion channels |
| JP2008540438A (ja) | 2005-05-04 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なピリジン |
| JP2008540665A (ja) | 2005-05-19 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なビアリール |
| PT1928886E (pt) * | 2005-09-09 | 2011-07-14 | Glaxosmithkline Llc | Derivados de piridina e sua utilização para o tratamento de distúrbios psicóticos |
| US7855218B2 (en) | 2005-10-10 | 2010-12-21 | Convergence Pharmaceuticals Limited | Compounds |
| TW200728258A (en) * | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| EP2117538A1 (en) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
-
2006
- 2006-10-05 TW TW095136986A patent/TW200730494A/zh unknown
- 2006-10-06 US US11/570,560 patent/US7655693B2/en active Active
- 2006-10-06 AU AU2006301470A patent/AU2006301470B2/en not_active Ceased
- 2006-10-06 JP JP2008534910A patent/JP5139305B2/ja not_active Expired - Fee Related
- 2006-10-06 PL PL06806110T patent/PL1934177T3/pl unknown
- 2006-10-06 BR BRPI0616944A patent/BRPI0616944B8/pt not_active IP Right Cessation
- 2006-10-06 ES ES06806110T patent/ES2387405T3/es active Active
- 2006-10-06 KR KR1020087011271A patent/KR101282464B1/ko not_active Expired - Fee Related
- 2006-10-06 EA EA200801054A patent/EA015736B1/ru not_active IP Right Cessation
- 2006-10-06 NZ NZ567051A patent/NZ567051A/en unknown
- 2006-10-06 CA CA2625642A patent/CA2625642C/en active Active
- 2006-10-06 PE PE2006001225A patent/PE20070592A1/es not_active Application Discontinuation
- 2006-10-06 AT AT06806110T patent/ATE556049T1/de active
- 2006-10-06 WO PCT/EP2006/009731 patent/WO2007042239A1/en not_active Ceased
- 2006-10-06 EP EP06806110A patent/EP1934177B8/en active Active
- 2006-10-09 AR ARP060104441A patent/AR056575A1/es not_active Application Discontinuation
-
2008
- 2008-03-31 MA MA30797A patent/MA29817B1/fr unknown
- 2008-04-18 CR CR9898A patent/CR9898A/es not_active Application Discontinuation
- 2008-05-07 NO NO20082145A patent/NO20082145L/no not_active Application Discontinuation
- 2008-07-03 IL IL192627A patent/IL192627A0/en active IP Right Grant
-
2009
- 2009-12-17 US US12/641,111 patent/US8153681B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009511519A (ja) | 2009-03-19 |
| EP1934177A1 (en) | 2008-06-25 |
| ES2387405T3 (es) | 2012-09-21 |
| CA2625642A1 (en) | 2007-04-19 |
| JP5139305B2 (ja) | 2013-02-06 |
| PE20070592A1 (es) | 2007-06-23 |
| KR101282464B1 (ko) | 2013-07-04 |
| PL1934177T3 (pl) | 2013-03-29 |
| AU2006301470B2 (en) | 2012-06-14 |
| NZ567051A (en) | 2011-03-31 |
| MA29817B1 (fr) | 2008-09-01 |
| TW200730494A (en) | 2007-08-16 |
| AU2006301470A1 (en) | 2007-04-19 |
| CR9898A (es) | 2008-07-29 |
| US8153681B2 (en) | 2012-04-10 |
| BRPI0616944B1 (pt) | 2020-04-14 |
| BRPI0616944A2 (pt) | 2011-07-05 |
| EA200801054A1 (ru) | 2008-08-29 |
| US7655693B2 (en) | 2010-02-02 |
| US20080280969A1 (en) | 2008-11-13 |
| IL192627A0 (en) | 2011-08-01 |
| ATE556049T1 (de) | 2012-05-15 |
| BRPI0616944B8 (pt) | 2021-05-25 |
| WO2007042239A1 (en) | 2007-04-19 |
| EP1934177B1 (en) | 2012-05-02 |
| US20100105754A1 (en) | 2010-04-29 |
| CA2625642C (en) | 2013-12-24 |
| NO20082145L (no) | 2008-05-07 |
| KR20080059296A (ko) | 2008-06-26 |
| EP1934177B8 (en) | 2012-09-05 |
| EA015736B1 (ru) | 2011-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056575A1 (es) | Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararlo | |
| CO6160236A2 (es) | Inhibidor de quinasa | |
| AR053162A1 (es) | Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma. | |
| AR071187A1 (es) | Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer | |
| CY1112921T1 (el) | Ενεργοποιητες γλυκοκινασης πυρρολιδινονης | |
| AR047992A1 (es) | Diaminopirimidinas como antagonistas de p2x3 y p2x2/3 | |
| ECSP055774A (es) | Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| UY28489A1 (es) | Glucopiranosiloxi-pirazoles, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparación | |
| ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| AR058780A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| UY30310A1 (es) | Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| MX2009001660A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis. | |
| BR112013031121A2 (pt) | composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento | |
| UA101393C2 (ru) | КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ | |
| CY1111442T1 (el) | Ενωσεις πιπεριδινης και χρησεις αυτων | |
| AR077139A1 (es) | Composiciones farmaceuticas utiles para tratar el vch | |
| AR062393A1 (es) | Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| AR055009A1 (es) | Compuesto profarmaco de amida de gemcitabina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento | |
| UY27018A1 (es) | Derivados de la pirimidina | |
| AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| CL2008002096A1 (es) | Combinacion farmaceutica que comprende un antagonista del receptor vanilloide vr-1 y un antiinflamatorio no esteroidal o una sal o solvato de cualquiera o de ambos compuestos; composicion farmaceutica que comprende dicha combinacio; y su uso de la combinacion para tratar un trastorno mediado por ek receptor vainilloide vr1. | |
| AR106180A2 (es) | COMPUESTO DE a-AMINOCARBOXIAMIDA QUE ES 5-(4-{[(2-FLUOROFENIL)METIL]OXI}FENIL)PROLINAMIDA | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |